Blocking the IL-6R is a major therapeutic advance for many diseases in adults and children. Updated consensus statement provides guidance to rheumatologists and other experts, as well as patients and administrators, on managing patients with the use of drugs blocking the IL-6 pathway.

With a variety of new developments and significant advancements in data, since the first version of this consensus statement, almost 10 years ago, Altaha, et al. summarise the current state of these agents in terms of efficacy and safety and provide a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders.